GLAXOSMITHKLINE PHARMACEUTICALS
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| CEPS(Rs) | 58.70 | 38.94 | 39.75 | 26.50 | 21.60 |
| DPS(Rs) | 54.00 | 32.00 | 32.00 | 90.00 | 30.00 |
| Book NAV/Share(Rs) | 116.06 | 105.47 | 102.89 | 157.19 | 87.26 |
| Tax Rate(%) | 26.38 | 27.72 | 27.35 | 51.12 | 36.72 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.56 | 24.01 | 24.73 | 21.20 | 19.14 |
| EBIT Margin(%) | 30.59 | 21.61 | 25.78 | 21.73 | 14.64 |
| Pre Tax Margin(%) | 30.56 | 21.57 | 25.72 | 21.67 | 14.53 |
| PAT Margin (%) | 22.50 | 15.59 | 18.69 | 10.59 | 9.19 |
| Cash Profit Margin (%) | 24.12 | 17.43 | 20.71 | 12.49 | 11.71 |
| Performance Ratios | |||||
| ROA(%) | 25.15 | 17.87 | 15.76 | 10.11 | 9.52 |
| ROE(%) | 49.43 | 33.43 | 27.58 | 18.39 | 17.42 |
| ROCE(%) | 67.64 | 46.49 | 38.06 | 37.72 | 27.74 |
| Asset Turnover(x) | 1.12 | 1.15 | 0.84 | 0.95 | 1.04 |
| Sales/Fixed Asset(x) | 6.20 | 5.84 | 5.31 | 6.03 | 3.04 |
| Working Capital/Sales(x) | 2.74 | 2.97 | 2.78 | 1.79 | 4.68 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.16 | 0.17 | 0.19 | 0.17 | 0.33 |
| Receivable days | 22.78 | 19.98 | 22.32 | 21.37 | 18.42 |
| Inventory Days | 44.57 | 47.50 | 55.82 | 54.91 | 60.14 |
| Payable days | 174.99 | 144.03 | 143.05 | 140.69 | 119.53 |
| Valuation Parameters | |||||
| PER(x) | 52.55 | 55.80 | 36.73 | 16.62 | 68.13 |
| PCE(x) | 49.02 | 49.90 | 33.31 | 62.75 | 66.69 |
| Price/Book(x) | 24.79 | 18.42 | 12.87 | 10.58 | 16.51 |
| Yield(%) | 1.88 | 1.65 | 2.42 | 5.41 | 2.08 |
| EV/Net Sales(x) | 12.63 | 9.22 | 6.54 | 7.84 | 7.94 |
| EV/Core EBITDA(x) | 35.77 | 30.89 | 23.51 | 30.67 | 32.80 |
| EV/EBIT(x) | 37.54 | 38.94 | 25.38 | 32.89 | 50.80 |
| EV/CE(x) | 24.26 | 17.92 | 12.22 | 5.68 | 7.72 |
| M Cap / Sales | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.56 | 6.21 | -0.80 | 12.05 | -9.27 |
| Core EBITDA Growth(%) | 28.32 | 13.96 | 8.03 | 18.19 | -3.74 |
| EBIT Growth(%) | 54.18 | -2.41 | 7.32 | 70.71 | 46.60 |
| PAT Growth(%) | 57.23 | -2.91 | 59.58 | 32.55 | 208.21 |
| EPS Growth(%) | 57.23 | -3.39 | -63.97 | 373.19 | 284.26 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 1.79 | 1.84 | 1.88 | 2.18 | 1.49 |
| Quick Ratio(x) | 1.54 | 1.49 | 1.53 | 1.87 | 1.09 |
| Interest Cover(x) | 960.03 | 454.77 | 462.54 | 391.29 | 129.56 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLAXOSMITHKLINE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAXOSMITHKLINE PHARMACEUTICALS | ₹43,898.3 Cr | 3.3% | 4.6% | 9.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹428,581.0 Cr | -1.8% | 4.1% | -1.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,051.0 Cr | -2.8% | -3.7% | 2.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,367.0 Cr | -0.2% | -0.9% | 12.9% | Stock Analytics | |
| CIPLA | ₹120,289.0 Cr | -2.1% | -1.7% | 0.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,421.0 Cr | -2% | 3.3% | -0.6% | Stock Analytics | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | 3.3% |
4.6% |
9.1% |
| SENSEX | -0.8% |
1% |
3.2% |
You may also like the below Video Courses
